Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): Genomic and updated efficacy dataCharles E. Geyer, David Cameron, M. S. Berger et al.|Journal of Clinical Oncology|2007Cited by 32
Investigation of tumor biomarkers as response predictors in a monotherapy study with lapatinib (L) as a first line treatment in ErbB2 amplified women with breast cancerHenry Gómez, Adrián Martín, Miguel A. Chavez et al.|Journal of Clinical Oncology|2007Cited by 11